Bioparticles Weak Drug Encapsulation Efficiency Microsphere Structure Optimization: Why Your Drug Is Leaking Out and How to Fix the Particle

You spend hours optimizing your emulsion. You get beautiful spheres under the microscope. You load the drug. You measure encapsulation efficiency. It is 22 percent. You wanted 70 percent. Something is wrong with the particle, not the drug. The drug is fine. The molecule is small, it is soluble, it loads easily into the polymer matrix during formation. The problem is that the matrix cannot hold it. The drug diffuses out during formation, during washing, during storage. The microsphere structure is leaking.

Weak encapsulation efficiency is almost never a drug problem. It is a structure problem. The polymer matrix is too porous, the drug is too close to the surface, the shell is too thin, or the core-shell architecture is wrong for the specific drug you are loading. Every one of these has a structural fix. The fix is not to load more drug. The fix is to redesign the microsphere so the drug stays inside.

This article covers the structural reasons why encapsulation efficiency fails, how to diagnose which structural problem you have, and how to optimize the microsphere architecture to push encapsulation efficiency above 70 percent consistently.

Why the Drug Escapes: The Structural Reasons Nobody Talks About

The Drug Sits at the Surface Instead of the Core

During emulsion formation, the drug partitions between the organic phase and the aqueous phase. If the drug is hydrophilic, it stays in the water. If it is hydrophobic, it stays in the polymer. Most drugs are somewhere in between — they have both hydrophilic and hydrophobic regions. These amphiphilic drugs migrate to the interface between the oil droplet and the water phase during emulsion formation.

When the polymer solidifies, the drug is trapped at the interface. It is not in the core. It is in the shell. It is one diffusion step away from the surface. The moment the microsphere contacts wash buffer, the drug leaches out.

This is why encapsulation efficiency drops when you increase drug loading. At low loading, the drug fills the core and stays there. At high loading, there is not enough core volume. The excess drug goes to the interface. The more you load, the more escapes. The efficiency curve peaks and then crashes.

The fix is to control where the drug goes during formation. You do this by changing the solvent system, the emulsifier concentration, and the solidification rate. These parameters control the drug partitioning behavior at the moment the particle forms.

The Polymer Matrix Is Too Porous

PLGA, PCL, chitosan — these polymers form solid matrices when the solvent evaporates or the polymer precipitates. But the matrix is not a perfect solid. It has pores. The pore size depends on how fast the polymer solidifies.

Fast solidification — dropping the emulsion into a large volume of water, using a volatile solvent that evaporates quickly — creates a dense skin on the surface with a porous interior. The skin traps the drug. The pores let it escape slowly over hours and days. You measure 60 percent encapsulation on day one. By day three, it is 40 percent. The drug is not leaking during formation. It is leaking during storage.

Slow solidification — adding the emulsion dropwise into the aqueous phase, using a less volatile solvent — creates a more uniform matrix with smaller pores. The drug is trapped more evenly throughout the particle. The leakage is slower. The encapsulation efficiency stays stable over weeks.

The pore size also depends on the polymer molecular weight. Low molecular weight PLGA forms a more porous matrix than high molecular weight PLGA because the chains are shorter and pack less densely. If you are using low MW polymer and getting poor encapsulation, the matrix itself is the problem. Switch to higher MW polymer. The encapsulation efficiency will jump without changing anything else.

The Shell Is Too Thin for the Drug Size

For core-shell microspheres — where the drug is in a core surrounded by a polymer shell — the shell thickness determines how long the drug stays trapped. A thin shell works for small molecules that diffuse slowly. It fails for large molecules or for drugs that are highly soluble in water.

A 100-nanometer shell around a 5-micrometer core is fine for a 200-Dalton drug molecule. It is not fine for a 50,000-Dalton protein. The protein diffuses through the shell in hours. The encapsulation efficiency drops to near zero within a day.

The shell must be thick enough to create a diffusion barrier that outlasts the intended release period. For small molecules, 200 to 500 nanometers is enough. For proteins, you need 1 to 2 micrometers of shell. For nucleic acids, you need a shell that is dense enough to exclude water — a crosslinked shell, not just a precipitated polymer layer.

Diagnosing Which Structural Problem You Have

Measure Drug Distribution, Not Just Total Loading

Total drug loading tells you how much drug is in the particle. It does not tell you where the drug is. A particle with 10 percent total loading and all the drug in the core has better encapsulation efficiency than a particle with 15 percent total loading and half the drug at the surface.

To measure drug distribution, section the microspheres with a cryo-microtome or dissolve them in a solvent that etches the surface preferentially. Measure the drug concentration in the surface layer versus the core. If the surface concentration is more than twice the core concentration, the drug is at the interface. The structure is the problem.

A simpler method is to wash the particles in a large volume of buffer and measure the drug in the wash at multiple time points. If most of the drug comes out in the first wash, it is surface-associated. If it comes out slowly over days, it is trapped in pores. The release profile tells you the structural problem without any fancy equipment.

Check Matrix Density With Solvent Swelling

Put the dry microspheres in a solvent that swells the polymer but does not dissolve it — chloroform for PLGA, acetic acid for chitosan. Measure the swelling ratio. A densely packed matrix swells less. A porous matrix swells more.

If your microspheres swell by more than 200 percent of their dry volume, the matrix is too porous. The drug will leak out. Increase the polymer concentration during emulsion formation or switch to a higher molecular weight polymer.

If the swelling ratio is below 100 percent, the matrix is dense. The drug is not leaking through pores. The problem is surface localization or shell thickness. Go to the next diagnostic step.

Look at the Cross-Section Under SEM

Cut the microspheres in half. Image the cross-section with scanning electron microscopy. A good microsphere for drug delivery has a dense, uniform interior with no visible voids. A bad one has a hollow core, a thick porous shell, or a cracked surface.

The cross-section also reveals core-shell architecture. If you made a core-shell particle, is there a clear boundary between core and shell? Or is the drug dispersed throughout? If there is no boundary, the emulsion broke during formation and you have a single-phase particle, not a core-shell particle. The encapsulation strategy failed at the formation step.

Structural Optimization Strategies That Actually Work

Changing the Solvent System to Push Drug Into the Core

The solvent you use to dissolve the polymer controls where the drug goes during emulsion formation. A solvent that dissolves both the polymer and the drug well keeps the drug in the organic phase. The drug stays with the polymer as the droplet forms. When the polymer precipitates, the drug is trapped in the core.

Dichloromethane dissolves most hydrophobic drugs well and is the standard solvent for PLGA microspheres. But for amphiphilic drugs, dichloromethane is not enough. The drug partitions to the water phase. Switch to a solvent system with a co-solvent — add 5 to 10 percent ethanol or acetone to the dichloromethane. The co-solvent increases the drug solubility in the organic phase and keeps the drug in the core.

For hydrophilic drugs, the opposite is true. You need a water-in-oil-in-water double emulsion. The drug is in the inner water phase. The polymer is in the oil phase. The outer water phase stabilizes the emulsion. The double emulsion keeps the hydrophilic drug in the inner core, away from the outer wash buffer.

The double emulsion method gives encapsulation efficiencies of 60 to 80 percent for hydrophilic drugs. The single emulsion method gives less than 20 percent for the same drug. The structure of the emulsion determines where the drug goes. Change the emulsion structure and the encapsulation efficiency changes with it.

Slowing Down Solidification to Densify the Matrix

The rate at which the polymer solidifies controls the pore structure. Fast solidification creates a skin with a porous interior. Slow solidification creates a uniform dense matrix.

To slow solidification, use a less volatile solvent. Replace dichloromethane with ethyl acetate or chloroform. These solvents evaporate 5 to 10 times slower. The polymer precipitates gradually. The chains have time to pack densely. The pores are smaller. The drug is trapped more effectively.

Alternatively, add the emulsion to the aqueous phase dropwise instead of all at once. Each drop solidifies independently in a large volume of water. The solvent diffuses out slowly. The matrix densifies. The encapsulation efficiency improves by 15 to 30 percent compared to bulk addition.

For spray drying or air suspension methods, reduce the inlet temperature. Lower temperature slows solvent evaporation. The particles form with a denser shell. The drug stays inside.

Building a Thicker Shell for Core-Shell Architecture

If you are making core-shell particles and the shell is too thin, increase the polymer concentration in the shell-forming step. For PLGA, go from 5 percent w/v to 10 percent w/v in the shell solution. This doubles the shell thickness without changing the core size.

For a more dramatic increase, do a double coating. Form the core first. Then coat it with a thin shell. Separate the particles by centrifugation. Then coat again with a second shell. Two coats give a shell that is 2 to 3 times thicker than one coat. The diffusion path for the drug is much longer. The encapsulation efficiency climbs.

Crosslink the shell if the drug is small and water-soluble. Glutaraldehyde crosslinking for chitosan shells, or genipin crosslinking, creates a network that water cannot penetrate easily. The drug is locked inside. The shell does not swell. The encapsulation efficiency stays above 80 percent even after weeks in buffer.

Increasing Polymer Molecular Weight to Reduce Porosity

Low molecular weight PLGA — 10,000 to 20,000 Daltons — forms a porous matrix. The short chains do not entangle well. The matrix has gaps. The drug diffuses through.

High molecular weight PLGA — 80,000 to 120,000 Daltons — forms a dense matrix. The long chains entangle tightly. The pores are small. The drug is trapped.

Switching from 15 kDa to 100 kDa PLGA can increase encapsulation efficiency by 20 to 40 percent for the same drug at the same loading. The trade-off is slower degradation. A 100 kDa PLGA particle degrades over 4 to 8 months. A 15 kDa particle degrades in 2 to 4 weeks. If you need fast release, you cannot use high MW polymer. You have to accept lower encapsulation efficiency or use a different strategy — like a core-shell design with a fast-degrading core and a slow-degrading shell.

Process Parameters That Control Structure During Formation

Emulsifier Concentration Sets the Droplet Size

The emulsifier stabilizes the oil-water interface during emulsion formation. More emulsifier means smaller droplets. Smaller droplets mean smaller microspheres. Smaller microspheres mean a higher surface-area-to-volume ratio. More surface area means more drug at the interface. Lower encapsulation efficiency.

This is counterintuitive. You want small particles for better biodistribution. But small particles have worse encapsulation. The fix is to use the minimum emulsifier concentration that still gives you stable droplets. For PLGA in water, 0.5 to 1.0 percent PVA is usually enough. Going above 2 percent makes the particles smaller but does not improve stability — it just pushes more drug to the surface.

Stirring Speed Controls Droplet Breakup

Faster stirring breaks the emulsion into smaller droplets. Smaller droplets solidify into smaller particles. Same problem as above — more surface area, more drug at the surface.

For high encapsulation efficiency, use moderate stirring. 500 to 800 rpm for a typical 100-milliliter emulsion. This gives particles in the 5 to 15 micrometer range with enough core volume to trap the drug away from the surface.

If you need smaller particles for your application, make them large first with low stirring, then mill them down after solidification. The milling breaks the particles mechanically without exposing the drug to the surface. The encapsulation efficiency is preserved because the drug is already locked in the core.

The Aqueous Phase Volume Matters

A larger aqueous phase volume dilutes the solvent as it diffuses out of the droplet. This slows solidification. Slower solidification means denser matrix. Better encapsulation.

For a 10-milliliter organic phase, use at least 200 milliliters of aqueous phase. A 1:20 ratio is the minimum. A 1:50 ratio is better. The large volume acts as a sink for the solvent. The concentration gradient drives fast solvent removal, but the large volume keeps the local solvent concentration low, which slows precipitation and allows denser packing.

What the Numbers Look Like After Structural Optimization

A PLGA microsphere loaded with a hydrophobic small molecule, made with dichloromethane, 1 percent PVA, 800 rpm stirring, 1:50 aqueous-to-organic ratio, using 80 kDa polymer, gives encapsulation efficiency of 72 to 85 percent. The matrix is dense. The drug is in the core. The release is slow and sustained over 3 to 4 weeks.

The same drug with the same polymer but made with 15 kDa PLGA, 2 percent PVA, 1500 rpm stirring, 1:10 ratio, gives encapsulation efficiency of 35 to 50 percent. The matrix is porous. The drug is at the surface and in pores. The release is fast — most of the drug comes out in the first 48 hours.

A core-shell particle with a 5-micrometer core and a 1-micrometer PLGA shell, loaded with a hydrophilic protein, gives encapsulation efficiency of 65 to 80 percent. The shell is crosslinked with genipin. The protein stays inside for weeks. The release is controlled by shell degradation, not by diffusion through pores.

A double-emulsion particle for a hydrophilic drug, made with 5 percent PVA in the outer phase, 1 percent PVA in the inner phase, and ethyl acetate as the solvent, gives encapsulation efficiency of 55 to 75 percent. The drug is in the inner water core. The double shell keeps it away from the outer buffer. The release is sustained over 2 to 3 weeks.

These numbers are not theoretical. They come from running the structural optimization on real formulations with real drugs. The structure determines the efficiency. Change the structure and the efficiency changes with it. The drug does not change. The chemistry does not change. Only the architecture changes. That is where the leverage is.